What do gastrin levels evaluate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What Gastrin Levels Evaluate

Gastrin levels primarily evaluate for gastrin-secreting tumors (gastrinomas/Zollinger-Ellison syndrome), distinguish types of gastric neuroendocrine tumors, and identify causes of hypergastrinemia including atrophic gastritis, pernicious anemia, and medication effects from proton pump inhibitors. 1, 2

Primary Clinical Indications for Gastrin Testing

Suspected Gastrinoma/Zollinger-Ellison Syndrome

Gastrin levels should be measured when evaluating patients with:

  • High-volume watery diarrhea (>1 liter/day) with dehydration and hypokalemia when other causes have been excluded 1
  • Severe or recurrent peptic ulcers, particularly those located in unusual anatomical locations (beyond the duodenal bulb, in the descending duodenum or jejunum), multiple ulcers, or ulcers refractory to standard therapy 1, 2, 3
  • Chronic diarrhea with gastroesophageal reflux disease refractory to standard therapy and weight loss 2
  • Recurrent peptic ulcer disease with gastrointestinal bleeding in the absence of H. pylori infection 1
  • Suspected MEN-1 syndrome (all gastrinoma patients should be evaluated for MEN-1) 1, 2

Diagnostic Interpretation

Fasting serum gastrin >1000 pg/mL combined with gastric pH <2 is diagnostic of gastrinoma 1, 3. Normal gastrin levels are approximately 150 pg/mL, with gastrinoma patients averaging around 1000 pg/mL 1. However, critical pitfall: comparable elevations occur in pernicious anemia, atrophic gastritis, and with proton pump inhibitor therapy 1.

Differential Diagnosis of Hypergastrinemia

Medication-Induced Hypergastrinemia

Proton pump inhibitors (PPIs) and H2 antagonists elevate both gastrin and chromogranin A levels 1, 4. PPIs should be withdrawn with great caution and ideally stopped 10-14 days before measuring fasting gastrin 1, 4. H2 antagonists should be interrupted 48 hours before testing 1. This is the most common cause of spurious hypergastrinemia in clinical practice 5.

Gastric Neuroendocrine Tumor Classification

Gastric pH is the key discriminator between NET types 6:

  • Type 1 gastric NETs (70-80% of gastric NETs): pH >4-5 indicates achlorhydria from atrophic gastritis with physiologic hypergastrinemia from parietal cell loss 6
  • Type 2 gastric NETs: pH <2 indicates gastrinoma/Zollinger-Ellison syndrome 6
  • Type 3 gastric NETs: Gastrin is not elevated 1

Other Causes of Elevated Gastrin

Raised gastrin levels also occur in:

  • Renal insufficiency (common cause that must be ruled out before pursuing ZES diagnosis) 2
  • Diabetes mellitus 1
  • Rheumatoid arthritis 1

Confirmatory Testing Algorithm

When gastrin is elevated but <10 times normal with gastric pH <2:

  1. Document increased basal acid output (BAO): BAO >15 mmol/h is indicative of gastrinoma in the presence of raised serum gastrin 1
  2. Calculate BAO/MAO ratio: Ratio >0.6 is highly specific for gastrinoma 7
  3. Secretin stimulation test: May be necessary in equivocal cases 1

Important contraindications: Basal acid output testing is inappropriate in patients with atrophic gastritis, pernicious anemia, or if PPIs have been used in the previous 14 days 1.

Clinical Context and Limitations

Gastrin testing for hormone-secreting tumors is extremely rare and should only be performed in high-volume watery diarrhea when other causes have been excluded 1. The prevalence of gastrinomas is approximately 1 per million cases per year 1.

Serum gastrin levels fluctuate, so the assay should be performed during an episode of diarrhea 1. Fasting specimens are required after an overnight fast to establish baseline values 4.

Increased gastrin causes enterochromaffin-like (ECL) cell hyperplasia and increased serum chromogranin A (CgA) levels, which may cause false positive results in diagnostic investigations for neuroendocrine tumors 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Management of Zollinger-Ellison Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gastrin Secretion and Diagnostic Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Persistent Hypergastrinemia After Gastric NET Resection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.